Pathologic changes in breast cancer following neoadjuvant chemotherapy: Implications for the assessment of response

Clinical Breast Cancer

Volumn 5, Issue 3, 2004, Pages 235-238

  Rajan, Radhika ^a   Esteva, Francisco J ^a   Symmans, W Fraser ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytopathology; Lymph nodes; Residual tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ACCURACY; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL EXAMINATION; CORRELATION ANALYSIS; CYTOPATHOLOGY; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MINIMAL RESIDUAL DISEASE; MORPHOMETRICS; PREOPERATIVE CARE; RADIOLOGY; TUMOR VOLUME;

EID: 12344266898     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.028     Document Type: Article

References (18)

1. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16:93-100.
2. Kuerer HM, Newman LA, Smith TL, et al. Clinical case of breast cancer patients with complete pathologic primary and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-467.
3. Machiavelli MR, Romero AO, Perez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998; 4:125-131.
4. Chollet PS, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86: 1041-1046.
5. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week therapy followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21:35a (Abstract #135).
6. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62:257-2516.
7. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18. Cancer 2002; 95:681-695.
8. Moll UM, Chumas J. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. Pathol Res Pract 1997; 193:187-196.
9. Morrow M, Braverman A, Thelma W, et al. Multimodal therapy for locally advanced breast cancer. Arch Surg 1986; 121:1291-1296.
10. Rasbridge SA, Gillet CE, Seymour AM, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994; 70:335-341.
11. Kennedy S, Merino MH, Swain SM, et al. The effect of hormonal and chemotherapy on tumoral and non-neoplastic breast tissue. Hum Pathol 1990; 21:192-198.
12. Miller WR, Dixon JK, Macfarlane L, et al. Pathologic features of breast cancer following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003; 39:462-468.
13. Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46:2578-2581.
14. Honkoop AH, Pinedo HM, De Jong, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997; 107:211-218.
15. Gajdos C, Tartter PJ, Estabrook A, et al. Relationship of clinical and pathological response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002; 80:4-11.
16. Aktepe F, Kapucuoglu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology 1996; 29:63-67.
17. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer, J Clin Oncol 1998; 16:2672-2685.
18. Rosen PP. Rosen's Breast Pathology. Philadelphia: Lipincott-Raven, 1997:779-787.